L-ARGININE CLINICAL TRIALS
ClinicalTrials.gov
United States National Institutes of Health (NIH)

Effectiveness of Arginine as a Treatment for Sickle Cell Anemia

ClinicalTrials.gov
Identifier: NCT00513617
Condition: Anemia, Sickle Cell




PURPOSE

Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited genetic disease that can cause intense pain episodes. This study will evaluate the effectiveness of the nutritional supplement arginine at improving blood cell function and disease symptoms in people with SCD.

SCD is an inherited blood disorder. Symptoms include anemia, infections, organ damage, and intense episodes of pain that are called "sickle cell crises." SCD is caused by an abnormal type of hemoglobin, which is a protein inside red blood cells that carries oxygen. In people with SCD, the abnormal hemoglobin distorts the shape of the red blood cells.

This causes the red blood cells to clump together, decreasing blood flow and oxygen delivery to the body's tissues. The reduced levels of oxygen can lead to sickle cell crises and tissue damage. Hemolysis, the destruction of red blood cells, is also a hallmark of SCD. During hemolysis, hemoglobin is released into the bloodstream, where it removes nitric oxide (NO), a natural chemical in the body that expands blood vessels.

Arginase, another protein released during hemolysis, removes arginine from the bloodstream, which can also lead to decreased NO levels. The lack of NO constricts blood vessels, further contributing to painful sickle cell crises.

Arginine supplementation may increase healthy hemoglobin and NO production and, in turn, prevent or reduce sickle cell crises. The purpose of this study is to evaluate the effectiveness of arginine at increasing NO levels, improving red blood cell function, and reducing hospitalizations and pain medication use in people with SCD.

This study will enroll children and adults with SCD. Participants will be randomly assigned to receive twice daily doses of either a low dose of arginine, a high dose of arginine, or placebo for 12 weeks. Study visits will occur at baseline, three times during Month 1, and Weeks 8, 12, 14, and 16. Each study visit will include an echocardiogram to measure heart activity, blood collection, and a medical history review to identify adverse events, pain medication usage, headaches, emergency department visits, and hospitalizations.

CONDITION: SICKLE CELL ANEMIA

INTERVENTION AGENT: L-ARGININE

TOTAL ENROLLMENT: 96 HUMAN SUBJECTS

PHASE: PHASE II – ARGININE vs PLACEBO

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Number of arms in study: 3

Official Title: Arginine Supplementation in Sickle Cell Anemia: Physiological and Prophylactic Effects

Primary Outcome Measures: NO levels, Gardos channel activity, and red blood cell density measurements. Time Frame: Measured at Weeks 4, 8, and 12.

Secondary Outcome Measures:

Soluble vascular cell adhesion molecule (sVCAM), nitrotyrosine, 8-iso-PGF2a, ektacytomotry, endothelial-1, fetal hemoglobin (HbF), and echocardiogram results [Time Frame: Measured at Weeks 4, 8, and 12]
Number of hospitalizations, number of emergency department visits, and pain medication use [Time Frame: Measured at Weeks 4, 8, and 12]

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Arms Assigned Interventions
Low Dose: Active Comparator 0.05 g/kg/day Drug: Arginine
High Dose: Active Comparator 0.10 g/kg/day Drug: Arginine
Placebo: Placebo Comparator Placebo


Eligibility

Ages Eligible for Study:
5 Years and above
Genders Eligible for Study: Both Criteria

Inclusion Criteria:

Established diagnosis of H SS or S-beta thalassemia
History of at least one vaso-occlusive pain event in the 12 months prior to study entry
Regular compliance with comprehensive medical care
In a steady disease state and not in the midst of any acute complication due to SCD at study entry


Exclusion Criteria:

Inability to take or tolerate oral medications
Liver dysfunction (i.e., SGPT level greater than or equal to two times the normal limit and albumin level less than or equal to 3.2 g/dL)
Kidney dysfunction ( i.e., creatinine level greater than or equal to 1.2 mg/dL for children and greater than or equal to 1.4 mg/dL for adults)
Allergy to arginine
Pregnant
Received a blood transfusion within the 90 days prior to study entry
More than 10 hospital admissions for pain in the 12 months prior to study entry
Daily use of opioids and experiencing unstable pain that interferes with work or daily routine
Required more than 3 hospital admissions and more than 10 emergency department/day hospital visits in the 12 months prior to study entry
  Received treatment with hydroxyurea within the 90 days prior to study entry
Received treatment with any investigational drug in the 90 days prior to study entry

Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients
Conditions: Anemia, Sickle Cell; Pneumonia

PATENTS FILED WITH UNITED STATES PTO FOR L-ARGININE TREATMENT IN SICKLE CELL ANEMIA & THALASSEMIA:
Allen, Ann de Wees
Research Team: Clair Francomano, M.D., Randall Maxey, M.D. PhD.,

Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)
Conditions: Anemia, Cooley's; Beta-Thalassemia; Hematologic Diseases; Thalassemia; Osteoporosis; Iron Overload; Hypertension, Pulmonary

Effects of L-Arginine Supplementation in Adults With Moderate to Severe Asthma
Condition: Asthma

Role of Nitric Oxide Scavenging by Plasma Hemoglobin and Identification of Hemolysis-Associated Pulmonary Hypertension in Malaria
Conditions: Malaria; Pulmonary Hypertension

Arginine Malaria Trial: Study of Adjunctive Arginine in Falciparum Malaria
Condition: Malaria, Falciparum

The Short Term Safety and Efficacy of Inhaled L-Arginine in Patients With Cystic Fibrosis
Condition: Cystic Fibrosis

Treatment of Alcohol-Related Hepatitis With Arginine
Condition: Alcoholic Hepatitis

Arginine Feeding: a Novel Strategy to Improve Protein Metabolism in Cancer and the Response to Surgery
Condition: Protein Metabolism

L-Arginine Metabolism in Essential Hypertension
Condition: Essential Hypertension

Study of Arginine Metabolism and Nitric Oxide Formation in Relation to Glutamine Supply in Severely Burned Patients.
Condition: Burn Injury

Nitric Oxide (NO) Donors and Inhibitors Study: Study to Evaluate L-Arginine and Aminoguanidine in Asthmatic Subjects
Condition: Asthma

Phase II Randomized Trial of Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers
Conditions: Skin Ulcers; Sickle Cell Anemia

L-Arginine Supplements in Treating Women Who Are Cancer Survivors
Conditions: Sexual Dysfunction and Infertility; Sexuality and Reproductive Issues; Unspecified Adult Solid Tumor, Protocol Specific

NO Donors and Inhibitors to Study Imbalance of Nitrogen Stress and Antioxidant Defense in COPD
Conditions: Healthy Volunteers (Non-Smoker); Healthy Volunteers (Smoker); Chronic Obstructive Pulmonary Disease

Nitric Oxide (NO) Activity and Diabetic Nephropathy
Condition: Diabetic Nephropathies


Role of Nitric Oxide in Cirrhosis: Relationship With Systemic Hemodynamics, Renal Function, Vasoactive Systems and Endotoxemia
Conditions: Cirrhosis; Liver Cirrhosis

A Study Investigating a New, Oral Growth Hormone Secretagogue (GHS)(ARD-07) as a Growth Hormone (GH) Stimulation Test
Conditions: Hypopituitarism; Hypothalamic Disease

Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing
Condition: Growth Hormone Deficiency

Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1
Conditions: Growth Failure; X-Linked Severe Combined Immunodeficiency (XSCID); Growth Hormone Resistence

Nutritional Effect of an Amino Acid Mixture on Lean Body Mass (LBM) in Post-Bariatric Surgery Patients
Conditions: Obesity; Post-Gastric Bypass





Encode®
Patents Pending in Genetic Polymorphisms




 
Copyright 2005 - 2011 Encode® Research Project